Cogent Biosciences, Inc.
General ticker "COGT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.1B (TTM average)
Cogent Biosciences, Inc. follows the US Stock Market performance with the rate: 46.5%.
Estimated limits based on current volatility of 4.0%: low 38.53$, high 40.25$
Factors to consider:
- Total employees count: 205 (+25.0%) as of 2024
- Top business risk factors: Cybersecurity threats, Insufficient funding, Labor/talent shortage/retention, Strategic risks and growth management, Lack of commercialized products
- Current price 203.1% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.60$, 12.97$]
- 2025-12-31 to 2026-12-31 estimated range: [3.69$, 10.83$]
Financial Metrics affecting the COGT estimates:
- Negative: with PPE of -4.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -25.72 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Investing cash flow per share per price, % of 4.74 > -0.66
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
Short-term COGT quotes
Long-term COGT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $147.84MM | $208.13MM | $275.94MM |
| Operating Income | $-147.84MM | $-208.13MM | $-275.94MM |
| Non-Operating Income | $7.60MM | $15.72MM | $20.08MM |
| R&D Expense | $121.63MM | $173.75MM | $232.66MM |
| Income(Loss) | $-140.24MM | $-192.41MM | $-255.86MM |
| Profit(Loss)* | $-140.24MM | $-192.41MM | $-255.86MM |
| Stockholders Equity | $255.74MM | $257.80MM | $256.29MM |
| Assets | $300.81MM | $313.44MM | $327.90MM |
| Operating Cash Flow | $-118.64MM | $-153.62MM | $-207.79MM |
| Capital expenditure | $6.86MM | $2.80MM | $0.57MM |
| Investing Cash Flow | $-124.72MM | $-97.82MM | $38.28MM |
| Financing Cash Flow | $163.56MM | $163.54MM | $214.45MM |
| Earnings Per Share** | $-2.39 | $-2.42 | $-2.46 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.